Exhibit 10.184

SETTLEMENT AGREEMENT AND AMENDMENT TO RSV LICENSE AGREEMENT

This Settlement Agreement and Amendment to RSV License Agreement (the "Settlement Agreement") is entered into this 16th day of December 2002 (the
"Effective Date") by and between MedImmune, Inc. ("MedImmune" or "Licensee"), and the Massachusetts Biologic Laboratories of the University of Massachusetts ("MBL" or "Licensor")
(collectively the "Parties");

WHEREAS,
reference is made to the RSV License Agreement dated August 1, 1989 by and between the Massachusetts Health Research Institute, Inc. ("MHRI"), Pediatric
Pharmaceuticals, Inc. ("PPI") and Molecular Vaccines, Inc. ("MVI"), as amended on September 30, 1998 (the "RSV License Agreement"). As
successor-in-interest to MHRI with respect to the RSV License Agreement, MBL is presently the sole Licensor thereunder. As successor-in-interest to PPI
and MVI with respect to the License Agreement, MedImmune is presently the sole Licensee thereunder;

WHEREAS,
MedImmune has developed and may hereafter develop monoclonal antibody(ies) that are Royalty Bearing Product (as defined in the RSV License Agreement); and

WHEREAS,
a dispute has arisen between MBL and MedImmune over MedImmune's compliance with its obligations under Section 2.5 of the RSV License Agreement to transfer information and
to provide technical assistance with regard to MedImmune's monoclonal antibody(ies) that are Royalty Bearing Product ("Dispute 1"); and

WHEREAS,
a further dispute has arisen between MBL and MedImmune over whether a Distribution Agreement ("Distribution Agreement"), dated December 1, 1997, between MedImmune and
Abbott International, Ltd. ("Abbott"), which designates Abbott as the exclusive distributor of Synagis® overseas, constitutes a sub-license under the RSV License
Agreement ("Dispute 2"); and

WHEREAS,
in connection with Dispute 1 and Dispute 2, MedImmune claimed that MBL acted in bad faith under the RSV License Agreement ("Dispute 3"); and

WHEREAS,
MBL and MedImmune have agreed to delete Section 2.5 of the RSV License Agreement covering the grant by MedImmune to MBL of a royalty free right and license to make, have
made, use and sell or have sold on its behalf any monoclonal antibody(ies) developed by MedImmune useful in the Field (as defined in the RSV License Agreement) for use within the Commonwealth of
Massachusetts and the State of Maine in consideration of an increased royalty for sales of such monoclonal antibodies in the Commonwealth of Massachusetts and the State of Maine, as set forth below;
and

WHEREAS,
MBL and MedImmune have mediated the above referenced disputes (the "Mediation"), have previously reached an agreement in principle resolving said disputes, and now wish formally
to memorialize the resolution of their differences and move forward with their cooperative efforts;

NOW,
THEREFORE, in consideration of the mutual benefits to be derived from this Settlement Agreement and the representations, conditions and promises hereinafter contained, the Parties
hereby agree as follows:

1.    Amendments to the RSV License Agreement



---





2

---



2.    Payments



3

---



3.    Return Of MedImmune's Proprietary Information



4.    Release



5.    Warranties and Representations



4

---



6.    General Provisions



|MedImmune, Inc. |  | MBL                                                                   
|--------------- |  | ----------------------------------------------------------------------
|                |  |                                                                       
|By:             |  | /s/DAVID M. MOTTTitle: Chief Executive Officer
Date: December 16, 2002

5

---

QuickLinks